Malignant Central Nervous System Neoplasm

Malignant Central Nervous System Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

2,864 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 823
Recruiting: 453
Ph III recruiting: 27
Growth YoY: +21.8%
Industry share: 16%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.9%
Trials / 1,000 deaths: 45.2 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (419)

clinicaltrialsPublishedShowing 1–50 of 359 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05432804	Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment	recruiting	Phase 1 / Phase 2	97	National Cancer Institute (NCI)NIH	1	Sep 28, 2026	clinicaltrials
NCT07326566	Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII	recruiting	Phase 2	162	Black Diamond Therapeutics, Inc.INDUSTRY	1	Sep 28, 2026